SCHEMBL6541579

SCHEMBL6541579

CCN(CC)CCOc1cc(NS(=O)(=O)c2c(C)cc(Br)cc2C)ccc1Cl

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.42
ALDH1A1 P00352 4/20 0.42
MAPT P10636 3/20 0.42
HTT P42858 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
FABP4 P15090 1/20 0.41
XBP1 P17861 2/20 0.41
GAA P10253 1/20 0.41
POLB P06746 1/20 0.40
HPGD P15428 1/20 0.40
UTS2R Q9UKP6 3/20 0.40
KDM4E B2RXH2 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
KDR P35968 3/20 0.37
HRH3 Q9Y5N1 1/20 0.37
EGFR P00533 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6542898 0.89 UTS2R (0.51) LMNAALDH1A1MAPTHTTMEN1
SCHEMBL6543128 0.81 UTS2R (0.47) LMNAALDH1A1MAPTHTTMEN1
SCHEMBL6542867 0.80 UTS2R (0.41) LMNAALDH1A1MAPTHTTMEN1
SCHEMBL6542907 0.80 UTS2R (0.60) LMNAALDH1A1MAPTHTTMEN1
SCHEMBL6542198 0.79 LMNA (0.41) LMNAALDH1A1MAPTHTTFABP4
SCHEMBL6541986 0.78 UTS2R (0.48) LMNAALDH1A1MAPTHTTMEN1
SCHEMBL6542874 0.77 LMNA (0.51) LMNAALDH1A1MAPTHTTMEN1
SCHEMBL6541691 0.77 LMNA (0.60) LMNAALDH1A1MAPTHTTMEN1
SCHEMBL6542669 0.74 UTS2R (0.53) LMNAALDH1A1MAPTHTTMEN1
SCHEMBL7247677 0.73 UTS2R (0.49) LMNAALDH1A1MAPTHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1248607-A4 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2004-10-06 EP claimed
US-20030100580-A1 Urotensin-II receptor antagonists SMITHKLINE BEECHAM CORPORATION 2003-05-29 US claimed
EP-1248607-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-10-16 EP claimed
WO-2001045694-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-06-28 WO claimed
EP-1248607-A4 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2004-10-06 EP disclosed
US-20030100580-A1 Urotensin-II receptor antagonists SMITHKLINE BEECHAM CORPORATION 2003-05-29 US disclosed
EP-1248607-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SmithKline Beecham Corporation (US) 2002-10-16 EP disclosed
WO-2001045694-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100580-A1 Urotensin-II receptor antagonists UTS2R, TMPRSS4, PLAUR LMNA 4591/4885ALDH1A1 4452/4885MAPT 3109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.